Preventive effect of tacrolimus on patients with post- endoscopic retrograde cholangiopancreatography pancreatitis
0
조회
0
다운로드
2
인용
0
참고문헌
키워드
초록
Background/Aims: In patients undergoing endoscopic retrograde cholangiopancreatography (ERCP), calcineurin activates zymogen, which results in pancreatitis. In this study, we aimed to determine the efficacy of tacrolimus, a calcineurin inhibitor, in preventing post-ERCP pancreatitis (PEP). Methods: This was a prospective pilot study in which patients who underwent ERCP received tacrolimus (4 mg in two divided doses); this was the Tac group. A contemporaneous cohort of patients was included as a control group. All patients were followed-up for PEP. PEP was characterized by worsening abdominal pain with an acute onset, elevated pancreatic enzymes, and a duration of hospital stay of more than 48 hours. Serum tacrolimus levels were measured immediately before the procedure in the Tac group. Results: There were no differences in the baseline characteristics between the Tac group (n=48) and the control group (n=51). Only four out of 48 patients (8.3%) had PEP in the Tac group compared to eight out of 51 patients (15.7%) who had PEP in the control group. The mean trough tacrolimus level in patients who developed PEP was significantly lower (p<0.05). Conclusions: Oral tacrolimus at a cumulative dose of 4 mg safely prevents PEP. Further randomized controlled studies are warranted to establish the role of tacrolimus in this context.
Abstract
Background/Aims: In patients undergoing endoscopic retrograde cholangiopancreatography (ERCP), calcineurin activates zymogen, which results in pancreatitis. In this study, we aimed to determine the efficacy of tacrolimus, a calcineurin inhibitor, in preventing post-ERCP pancreatitis (PEP). Methods: This was a prospective pilot study in which patients who underwent ERCP received tacrolimus (4 mg in two divided doses); this was the Tac group. A contemporaneous cohort of patients was included as a control group. All patients were followed-up for PEP. PEP was characterized by worsening abdominal pain with an acute onset, elevated pancreatic enzymes, and a duration of hospital stay of more than 48 hours. Serum tacrolimus levels were measured immediately before the procedure in the Tac group. Results: There were no differences in the baseline characteristics between the Tac group (n=48) and the control group (n=51). Only four out of 48 patients (8.3%) had PEP in the Tac group compared to eight out of 51 patients (15.7%) who had PEP in the control group. The mean trough tacrolimus level in patients who developed PEP was significantly lower (p<0.05). Conclusions: Oral tacrolimus at a cumulative dose of 4 mg safely prevents PEP. Further randomized controlled studies are warranted to establish the role of tacrolimus in this context.
참고문헌 (34)
- Cotton PB, "A lexicon for endoscopic adverse events: report of an ASGE workshop", Gastrointest Endosc, 71, pp.446~454 (2010)
- Gottlieb K, "ERCP and biliary endoscopic sphincterotomy-induced pancreatitis", Gastrointest Endosc Clin N Am, 8, pp.87~114 (1998)
- Freeman ML, "Adverse outcomes of ERCP", Gastrointest Endosc, 56, pp.S273~S282 (2002)
- Testoni PA, "Risk factors for post-ERCP pancreatitis in high-and low-volume centers and among expert and non-expert operators : a prospective multicenter study", Am J Gastroenterol, 105, pp.1753~1761 (2010)
- Freeman ML, "Risk factors for post-ERCP pancreatitis : a prospective, multicenter study", Gastrointest Endosc, 54, pp.425~434 (2001)
- Loperfido S, "Major early complications from diagnostic and therapeutic ERCP : a prospective multicenter study", Gastrointest Endosc, 48, pp.1~10 (1998)
- Masci E, "Complications of diagnostic and therapeutic ERCP : a prospective multicenter study", Am J Gastroenterol, 96, pp.417~423 (2001)
- Freeman ML, "Complications of endoscopic biliary sphincterotomy", N Engl J Med, 335, pp.909~918 (1996)
- Vandervoort J, "Risk factors for complications after performance of ERCP", Gastrointest Endosc, 56, pp.652~656 (2002)
- Cheng CL, "Risk factors for post-ERCP pancreatitis : a prospective multicenter study", Am J Gastroenterol, 101, pp.139~147 (2006)
- Cotton PB, "Risk factors for complications after ERCP : a multivariate analysis of 11, 497 procedures over 12 years", Gastrointest Endosc, 70, pp.80~88 (2009)
- Wang P, "Risk factors for ERCP-related complications : a prospective multicenter study", Am J Gastroenterol, 104, pp.31~40 (2009)
- Pezzilli R, "Mechanisms involved in the onset of post-ERCP pancreatitis", JOP, 3, pp.162~168 (2002)
- Wang ZK, "Is prophylactic somatostatin effective to prevent post-endoscopic retrograde cholangiopancreatography pancreatitis or hyperamylasemia? A randomized, placebo-controlled pilot trial", Chin Med J (Engl), 126, pp.2403~2408 (2013)
- Andriulli A, "Gabexate or somatostatin administration before ERCP in patients at high risk for post-ERCP pancreatitis : a multicenter, placebo-controlled, randomized clinical trial", Gastrointest Endosc, 56, pp.488~495 (2002)
- Zhang Y, "Meta-analysis : octreotide prevents post-ERCP pancreatitis, but only at sufficient doses", Aliment Pharmacol Ther, 29, pp.1155~1164 (2009)
- Yaghoobi M, "Meta-analysis : rectal indomethacin for the prevention of post-ERCP pancreatitis", Aliment Pharmacol Ther, 38, pp.995~1001 (2013)
- Sun HL, "Rectal NSAIDs for the prevention of post-ERCP pancreatitis : a meta-analysis of randomized controlled trials", Surgeon, 12, pp.141~147 (2014)
- Yuhara H, "Pharmacologic prophylaxis of post-endoscopic retrograde cholangiopancreatography pancreatitis : protease inhibitors and NSAIDs in a meta-analysis", J Gastroenterol, 49, pp.388~399 (2014)
- Sethi S, "A meta-analysis on the role of rectal diclofenac and indomethacin in the prevention of post-endoscopic retrograde cholangiopancreatography pancreatitis", Pancreas, 43, pp.190~197 (2014)
- Elmunzer BJ, "Does rectal indomethacin eliminate the need for prophylactic pancreatic stent placement in patients undergoing high-risk ERCP? Post hoc efficacy and cost-benefit analyses using prospective clinical trial data", Am J Gastroenterol, 108, pp.410~415 (2013)
- Tse F, "Guide wire-assisted cannulation for the prevention of post-ERCP pancreatitis : a systematic review and meta-analysis", Endoscopy, 45, pp.605~618 (2013)
- Andriulli A, "Pancreatic duct stents in the prophylaxis of pancreatic damage after endoscopic retrograde cholangiopancreatography : a systematic analysis of benefits and associated risks", Digestion, 75, pp.156~163 (2007)
- Mazaki T, "Prophylactic pancreatic stent placement and post-ERCP pancreatitis : an updated meta-analysis", J Gastroenterol, 49, pp.343~355 (2014)
- Orabi AI, "Targeted inhibition of pancreatic acinar cell calcineurin is a novel strategy to prevent post-ERCP pancreatitis", Cell Mol Gastroenterol Hepatol, 3, pp.119~128 (2017)
- Thiruvengadam NR, "Tacrolimus and indomethacin are safe and effective at reducing pancreatitis after endoscopic retrograde cholangiopancreatography in patients who have undergone liver transplantation", Clin Gastroenterol Hepatol, 18, pp.1224~1232 (2020)
- Holt DW, "Therapeutic drug monitoring of immunosuppressive drugs in kidney transplantation", Curr Opin Nephrol Hypertens, 11, pp.657~663 (2002)
- ASGE Standards of Practice Committee, "Adverse events associated with ERCP", Gastrointest Endosc, 85, pp.32~47 (2017)
- Law R, "Role of immunosuppression in post-endoscopic retrograde cholangiopancreatography pancreatitis after liver transplantation : a retrospective analysis", Liver Transpl, 19, pp.1354~1360 (2013)
- Bai Y, "Prophylactic corticosteroids do not prevent post-ERCP pancreatitis : a meta-analysis of randomized controlled trials", Pancreatology, 8, pp.504~509 (2008)
- Yang Z, "Immunosuppressants : pharmacokinetics, methods of monitoring and role of high performance liquid chromatography", mass spectrometry, 2005, pp.5, 405~430
- Baillie J, "Fifteen years of ERCP", Gastrointest Endosc, 86, pp.327~328 (2017)
- Xu J, "A case report : acute pancreatitis associated with tacrolimus in kidney transplantation", BMC Nephrol, 20, pp.209~ (2019)
- Nieto Y, "Acute pancreatitis during immunosuppression with tacrolimus following an allogeneic umbilical cord blood transplantation", Bone Marrow Transplant, 26, pp.109~111 (2000)